CD20-Negative Primary Bone Marrow Large B Cell Lymphoma: A Report of Two Cases with Review of Literature

We describe diagnostic and therapeutic challenges in this rare entity of CD20-negative B cell lymphomas. They comprise only 1 to 2% of all B cell lymphoma with four subcategories. However, with an increasing understanding of these cases, novel entities have been recognized. Workup, treatment, and fo...

Full description

Saved in:
Bibliographic Details
Published in:South Asian journal of cancer 2023-08
Main Authors: Jaiswal, Ankita, Gupta, Aastha, Dixit, Mallika, Patel, Govind, Mohanty, Sambit
Format: Article
Language:English
Subjects:
CD20-negative lymphomas
plasmablastic lymphomas
primary bone marrow lymphomas
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We describe diagnostic and therapeutic challenges in this rare entity of CD20-negative B cell lymphomas. They comprise only 1 to 2% of all B cell lymphoma with four subcategories. However, with an increasing understanding of these cases, novel entities have been recognized. Workup, treatment, and follow-up of two CD20-negative B cell lymphoma cases, including a novel entity, have been described. A novel case of triple expresser CD20-negative B cell lymphoma and plasmablastic lymphoma has been diagnosed. The absence of CD20 leads to the abolishment of the targeted drug (rituximab) from the treatment regimen. These cases render the importance of extensive immunohistochemistry and fluorescence in situ hybridization workup for diagnosis of this rare entity. Treatment also remains a challenge as immunotherapy with CD20-targeted drugs cannot be given.
ISSN:2278-330X
2278-4306
DOI:10.1055/s-0043-1768707